Predicting prognosis in stable angina-results from the Euro heart survey of stable angina: prospective observational study

Royal Brompton Hospital, London SW3 6NP.
BMJ (online) (Impact Factor: 17.45). 03/2006; 332(7536):262-7. DOI: 10.1136/bmj.38695.605440.AE
Source: PubMed


To investigate the prognosis associated with stable angina in a contemporary population as seen in clinical practice, to identify the key prognostic features, and from this to construct a simple score to assist risk prediction.
Prospective observational cohort study.
Pan-European survey in 156 outpatient cardiology clinics.
3031 patients were included on the basis of a new clinical diagnosis by a cardiologist of stable angina with follow-up at one year.
Death or non-fatal myocardial infarction.
The rate of death and non-fatal myocardial infarction in the first year was 2.3 per 100 patient years; the rate was 3.9 per 100 patient years in the subgroup (n = 994) with angiographic confirmation of coronary disease. The clinical and investigative factors most predictive of adverse outcome were comorbidity, diabetes, shorter duration of symptoms, increasing severity of symptoms, abnormal ventricular function, resting electrocardiogaphic changes, or not having any stress test done. Results of non-invasive stress tests did not significantly predict outcome in the population who had tests done. A score was constructed using the parameters predictive of outcome to estimate the probability of death or myocardial infarction within one year of presentation with stable angina.
A score based on the presence of simple, objective clinical and investigative variables makes it possible to discriminate effectively between very low risk and very high risk patients and to estimate the probability of death or non-fatal myocardial infarction over one year.

Download full-text


Available from: Anselm K Gitt,
  • Source
    • "Chronic stable angina pectoris (CSAP) is the most prevalent manifestation of IHD and affects up to 5% of the over-40-year-old population in most developed countries. In every one million people in the general population of most European countries, it is estimated that 20,000 to 40,000 individuals suffer from CSAP [2, 3]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background. Chronic stable angina pectoris (CSAP) is a major syndrome of ischemic heart disease (IHD). CSAP manifests as chest pain or discomfort and affects patients' quality of life. Acupoint application (AP) has been reported to be effective for managing the symptoms of CSAP, but the evidence is not convincing. Therefore, we designed a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of AP in the treatment of CSAP. Methods and Analysis. Two hundred participants with CSAP will be randomly assigned in a 1 : 1 : 1 : 1 ratio into 4 groups. All participants will receive 12 sessions of treatment in 4 weeks and the same basic treatment procedure. The participants will be visited and assessed for 12 weeks, including a 4-week screening, a 4-week treatment phase, and a 4-week follow-up phase. The primary outcome is the change in the total frequency of self-reported angina attack at 4th week compared with the baseline. The secondary outcomes include the intensity of angina pain, consumption of nitroglycerin or Suxiao Jiuxin pills, CCS angina classification, SAQ, SAS and SDS score. Ethics. The study protocol has been reviewed and approved by the Sichuan Regional Ethics Review Committee on TCM (number 2013kl-001). This trial is registered with NCT02029118.
    Evidence-based Complementary and Alternative Medicine 08/2014; 2014:619706. DOI:10.1155/2014/619706 · 1.88 Impact Factor
  • Source
    • "Recently, the Euro heart survey for SA [3], after recruiting more than 3,000 patients, determined the clinical and investigative factors to predict death or AMI in patients suffering from SA and also developed a prediction model to assist in prognostication of patients with a clinical diagnosis of SA. The presence of any comorbidity, such as diabetes, the severity of angina, shorter duration of symptoms, left ventricular dysfunction, and ST changes on the resting ECG, independently predicted outcome. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Inflammatory mediators appear to be the most intriguing yet confusing subject, regarding the management of patients with acute coronary syndromes (ACS). The current inflammatory concept of atherosclerotic coronary artery disease (CAD) led many investigators to concentrate on systemic markers of inflammation, as well as imaging techniques, which may be helpful in risk stratification and prognosis assessment for cardiovascular events. In this review, we try to depict many of the recently studied markers regarding stable angina (SA), their clinical usefulness, and possible future applications in the field.
    Disease markers 06/2014; 2014:831364. DOI:10.1155/2014/831364 · 1.56 Impact Factor
  • Source
    • "These data are routinely recorded for most patients before more costly information becomes available from further, often invasive, investigations. Other limitations of previous models include the use of selected samples from trials7,8 or voluntary registries,9 and covering a narrow range of SCAD such as excluding9 or being confined to post-ACS patients.7 Furthermore, the ACCF/AHA guidelines emphasize the importance of both all-cause mortality and coronary events as outcomes, but no previous studies have assessed both. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The population with stable coronary artery disease (SCAD) is growing but validated models to guide their clinical management are lacking. We developed and validated prognostic models for all-cause mortality and non-fatal myocardial infarction (MI) or coronary death in SCAD. Models were developed in a linked electronic health records cohort of 102 023 SCAD patients from the CALIBER programme, with mean follow-up of 4.4 (SD 2.8) years during which 20 817 deaths and 8856 coronary outcomes were observed. The Kaplan-Meier 5-year risk was 20.6% (95% CI, 20.3, 20.9) for mortality and 9.7% (95% CI, 9.4, 9.9) for non-fatal MI or coronary death. The predictors in the models were age, sex, CAD diagnosis, deprivation, smoking, hypertension, diabetes, lipids, heart failure, peripheral arterial disease, atrial fibrillation, stroke, chronic kidney disease, chronic pulmonary disease, liver disease, cancer, depression, anxiety, heart rate, creatinine, white cell count, and haemoglobin. The models had good calibration and discrimination in internal (external) validation with C-index 0.811 (0.735) for all-cause mortality and 0.778 (0.718) for non-fatal MI or coronary death. Using these models to identify patients at high risk (defined by guidelines as 3% annual mortality) and support a management decision associated with hazard ratio 0.8 could save an additional 13-16 life years or 15-18 coronary event-free years per 1000 patients screened, compared with models with just age, sex, and deprivation. These validated prognostic models could be used in clinical practice to support risk stratification as recommended in clinical guidelines.
    European Heart Journal 12/2013; 35(13). DOI:10.1093/eurheartj/eht533 · 15.20 Impact Factor
Show more